Scroll

labetalol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
aromatic ring -CH(-OH)-CH2-NH-R	1531	36894-69-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: labetalol labetalol hydrochloride albetol ibidomide labetalol HCl SCH 19927 SCH-19927	A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. Molecular weight: 328.41 Formula: C19H24N2O3 CLOGP: 2.50 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 95.58 ALOGS: -4.75 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

labetalol
labetalol hydrochloride
albetol
ibidomide
labetalol HCl
SCH 19927
SCH-19927

A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.

Molecular weight: 328.41
Formula: C19H24N2O3
CLOGP: 2.50
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 95.58
ALOGS: -4.75
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O
0.60	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	16 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	104.53 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	4.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	23 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.50 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 1, 1984	FDA	CNTY LINE PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	155.26	15.88	120	5601	120895	50478508
Caesarean section	102.59	15.88	45	5676	15594	50583809
Pre-eclampsia	101.14	15.88	37	5684	8007	50591396
Premature delivery	93.44	15.88	48	5673	23615	50575788
Premature baby	86.58	15.88	42	5679	18295	50581108
Maternal exposure during pregnancy	69.84	15.88	88	5633	159690	50439713
Foetal growth restriction	56.55	15.88	23	5698	6604	50592799
Patent ductus arteriosus	49.60	15.88	18	5703	3802	50595601
Premature labour	44.47	15.88	23	5698	11453	50587950
Pregnancy	43.69	15.88	32	5689	29545	50569858
Haemangioma congenital	43.12	15.88	10	5711	429	50598974
Foetal exposure during pregnancy	30.38	15.88	25	5696	27334	50572069
Low birth weight baby	29.34	15.88	14	5707	5867	50593536
Hypotension	28.48	15.88	74	5647	235395	50364008
Maternal drugs affecting foetus	28.15	15.88	13	5708	5064	50594339
HELLP syndrome	26.86	15.88	8	5713	911	50598492
Post transplant lymphoproliferative disorder	24.04	15.88	11	5710	4193	50595210
Gestational diabetes	23.41	15.88	13	5708	7452	50591951
Ultrasound uterus abnormal	22.77	15.88	4	5717	40	50599363
Phaeochromocytoma	22.44	15.88	6	5715	462	50598941
Foetal death	22.30	15.88	13	5708	8167	50591236
Exomphalos	21.45	15.88	6	5715	547	50598856
Dilatation intrahepatic duct acquired	20.54	15.88	6	5715	639	50598764
Hypertension	20.21	15.88	61	5660	211142	50388261
Hyperkalaemia	18.61	15.88	25	5696	48064	50551339
Abortion spontaneous	16.60	15.88	22	5699	41750	50557653
Cardiac arrest	16.51	15.88	32	5689	83619	50515784
Blood pressure increased	16.22	15.88	42	5679	133090	50466313
Frequent bowel movements	16.04	15.88	13	5708	13905	50585498

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature baby	110.02	18.47	49	3377	17231	29553870
Foetal disorder	72.10	18.47	17	3409	766	29570335
Low birth weight baby	70.07	18.47	27	3399	6581	29564520
Foetal exposure during pregnancy	66.52	18.47	44	3382	33823	29537278
Neutropenia neonatal	64.36	18.47	15	3411	642	29570459
Foetal growth restriction	45.74	18.47	17	3409	3749	29567352
Congenital oesophageal anomaly	44.24	18.47	8	3418	93	29571008
Polyhydramnios	31.62	18.47	7	3419	237	29570864
Maternal exposure during pregnancy	30.45	18.47	13	3413	4110	29566991
Patent ductus arteriosus	30.37	18.47	12	3414	3119	29567982
Anhedonia	29.21	18.47	15	3411	7185	29563916
Neonatal respiratory distress	26.38	18.47	7	3419	511	29570590
Newborn persistent pulmonary hypertension	24.79	18.47	5	3421	107	29570994
Emotional distress	24.72	18.47	17	3409	13878	29557223
Nephrogenic systemic fibrosis	24.47	18.47	11	3415	3931	29567170
Injury	24.16	18.47	19	3407	19027	29552074
Hypertension	22.80	18.47	45	3381	116569	29454532
Fear	22.73	18.47	14	3412	9490	29561611
Ventricular septal defect	22.39	18.47	10	3416	3519	29567582
Neonatal cholestasis	22.24	18.47	4	3422	45	29571056
Cardiac arrest	21.75	18.47	37	3389	85554	29485547
Pyelocaliectasis	21.12	18.47	7	3419	1102	29569999
Renal injury	19.38	18.47	13	3413	10189	29560912

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	136.07	15.45	92	6970	77583	64414087
Caesarean section	83.38	15.45	35	7027	11239	64480431
Pre-eclampsia	80.48	15.45	29	7033	6202	64485468
Premature labour	47.60	15.45	21	7041	7599	64484071
Maternal exposure during pregnancy	43.44	15.45	53	7009	95831	64395839
Hypotension	35.81	15.45	107	6955	380867	64110803
Hypertension	33.58	15.45	82	6980	259179	64232491
Pregnancy	32.43	15.45	23	7039	20842	64470828
Cardiac arrest	31.87	15.45	59	7003	154005	64337665
Kidney transplant rejection	28.77	15.45	16	7046	9495	64482175
Phaeochromocytoma	25.88	15.45	7	7055	582	64491088
Premature delivery	25.50	15.45	19	7043	18570	64473100
Anhedonia	23.38	15.45	16	7046	13690	64477980
Foetal growth restriction	22.14	15.45	8	7054	1722	64489948
Renal injury	21.68	15.45	16	7046	15413	64476257
Nephrogenic systemic fibrosis	20.85	15.45	11	7051	5881	64485789
Foetal death	20.79	15.45	11	7051	5919	64485751
Bradycardia	20.44	15.45	42	7020	118177	64373493
Dilatation intrahepatic duct acquired	20.29	15.45	6	7056	688	64490982
HELLP syndrome	20.25	15.45	6	7056	693	64490977
Mental status changes	20.24	15.45	29	7033	61133	64430537
Fear	19.92	15.45	17	7045	20154	64471516
Cerebrovascular accident	19.37	15.45	45	7017	137538	64354132
Renal failure	18.91	15.45	53	7009	181635	64310035
Myocardial infarction	18.88	15.45	50	7012	165771	64325899
Abortion spontaneous	18.57	15.45	18	7044	25125	64466545
Skin induration	18.28	15.45	9	7053	4166	64487504
Premature baby	17.21	15.45	8	7054	3264	64488406
Red blood cell schistocytes present	17.16	15.45	5	7057	545	64491125
Angioedema	17.15	15.45	27	7035	61794	64429876
Blood pressure increased	16.66	15.45	49	7013	172503	64319167
Cerebral haemorrhage	16.57	15.45	24	7038	51066	64440604
Cardiac failure congestive	16.54	15.45	41	7021	130539	64361131
Emotional distress	16.43	15.45	20	7042	36018	64455652
Coronary artery disease	16.22	15.45	26	7036	60407	64431263
Malignant hypertension	15.96	15.45	6	7056	1442	64490228
Post transplant lymphoproliferative disorder	15.95	15.45	11	7051	9533	64482137

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C07AG01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Alpha and beta blocking agents
ATC	C07BG01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Alpha and beta blocking agents and thiazides
ATC	C07CG01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND OTHER DIURETICS Alpha and beta blocking agents and other diuretics
FDA MoA	N0000000161	Adrenergic beta-Antagonists
FDA EPC	N0000175556	beta-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D000319	Adrenergic beta-Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013566	Sympathomimetics
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:66991	sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Angina pectoris	off-label use	194828000
Pheochromocytoma Adjunct Therapy	off-label use
Anuria	contraindication	2472002	DOID:2983
Bronchospasm	contraindication	4386001
Hypercholesterolemia	contraindication	13644009
Secondary angle-closure glaucoma	contraindication	21571006
Complete atrioventricular block	contraindication	27885002
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Depressive disorder	contraindication	35489007
Hyperuricemia	contraindication	35885006	DOID:1920
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Sinus bradycardia	contraindication	49710005
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hepatic failure	contraindication	59927004
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Pulmonary emphysema	contraindication	87433001
Cardiogenic shock	contraindication	89138009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hypomagnesemia	contraindication	190855004
Partial atrioventricular block	contraindication	195039008
Decompensated cardiac failure	contraindication	195111005
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Intraoperative floppy iris syndrome	contraindication	418801006
Azotemia	contraindication	445009001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.81	acidic
pKa2	12.65	acidic
pKa3	8.23	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	8.23	DRUG MATRIX	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	7.96	DRUG MATRIX	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.12	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.48	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.65	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.71	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.89	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.10	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	7.64	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	6.49	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.24	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	6.41	CHEMBL
CAAX prenyl protease 1	Enzyme		STE24_YEAST		AC50	5.11	CHEMBL
CAAX prenyl protease 2	Enzyme		RCE1_YEAST		AC50	4.82	CHEMBL

External reference:

ID	Source
4019797	VUID
N0000147886	NUI
D00600	KEGG_DRUG
32780-64-6	SECONDARY_CAS_RN
4018799	VANDF
4019797	VANDF
C0022860	UMLSCUI
CHEBI:6343	CHEBI
CHEMBL429	ChEMBL_ID
DB00598	DRUGBANK_ID
CHEMBL1200323	ChEMBL_ID
D007741	MESH_DESCRIPTOR_UI
3869	PUBCHEM_CID
7207	IUPHAR_LIGAND_ID
3941	INN_ID
R5H8897N95	UNII
202693	RXNORM
11828	MMSL
201477	MMSL
4950	MMSL
d00016	MMSL
001839	NDDF
004368	NDDF
372750000	SNOMEDCT_US
46547007	SNOMEDCT_US
50627005	SNOMEDCT_US
CHEMBL1204165	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9320	INJECTION	5 mg	INTRAVENOUS	ANDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9363	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9363	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9364	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9364	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9365	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9365	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9366	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9366	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9622	INJECTION	5 mg	INTRAVENOUS	ANDA	23 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9623	INJECTION	5 mg	INTRAVENOUS	ANDA	23 sections
Labetalol HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0010	TABLET, FILM COATED	100 mg	ORAL	ANDA	23 sections
Labetalol HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0117	TABLET, FILM COATED	200 mg	ORAL	ANDA	23 sections
Labetalol HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0118	TABLET, FILM COATED	300 mg	ORAL	ANDA	23 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2267	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	12 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2339	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	12 sections
Labetalol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0605	TABLET, FILM COATED	100 mg	ORAL	ANDA	22 sections
Labetalol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0606	TABLET, FILM COATED	200 mg	ORAL	ANDA	22 sections
Labetalol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0607	TABLET, FILM COATED	300 mg	ORAL	ANDA	22 sections
Labetalol HCL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8130	TABLET, FILM COATED	100 mg	ORAL	ANDA	22 sections
Labetalol HCL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8131	TABLET, FILM COATED	200 mg	ORAL	ANDA	22 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6252	INJECTION	5 mg	INTRAVENOUS	NDA	26 sections
Labetalol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5928	TABLET, FILM COATED	100 mg	ORAL	ANDA	22 sections
Labetalol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5929	TABLET, FILM COATED	200 mg	ORAL	ANDA	22 sections
Labetalol hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5930	TABLET, FILM COATED	300 mg	ORAL	ANDA	22 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7109	TABLET, FILM COATED	100 mg	ORAL	ANDA	19 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7110	TABLET, FILM COATED	200 mg	ORAL	ANDA	19 sections
Labetalol Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7111	TABLET, FILM COATED	300 mg	ORAL	ANDA	19 sections
Labetalol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-641	TABLET, FILM COATED	100 mg	ORAL	ANDA	23 sections
Labetalol	HUMAN PRESCRIPTION DRUG LABEL	1	10135-642	TABLET, FILM COATED	200 mg	ORAL	ANDA	23 sections